1

Supplemental Table 1. Baseline Characteristics of Study Subjects in Figure 2 (N=657), By Treatment

Control / PEG IFN / P-value
Patient Number / 329 / 328 / NA
Nonresponders, % / 80 / 80 / 0.981
Breakthrough/Relapsers, % / 20 / 20
Express,2 % / NA / NA
Age / 49.5 (7.0) / 51.1 (7.3) / 0.007
Male, % / 71 / 72 / 0.81
Caucasian, % / 72 / 72 / 0.95
Body Mass Index / 30.0 (5.4) / 29.8 (5.4) / 0.65
ALT/ULN / 2.34 (1.90) / 2.18 (1.69) / 0.25
Log10 HCV RNA / 6.45 (0.48) / 6.50 (0.47) / 0.18
Genotype 1, % / 92 / 96 / 0.03
Ishak Inflammation / 7.3 (2.0) / 7.5 (2.0) / 0.24
Ishak Fibrosis / 4.1 (1.3) / 4.0 (1.2) / 0.37
Ishak Fibrosis 5-6, % / 40 / 38 / 0.60

All values represent Means (± SD) or %. NA=not applicable.

1Compares the distribution of Nonresponders and Breakthrough/Relapsers between Control and Treated groups.

2Express patients received full-dose peginterferon/ribavirin therapy outside of the HALT-C Trial prior to enrollment.7

Supplemental Table 2. Baseline Characteristics of Study Subjects in Figure 2 (N=657), By Lead-in Virological Response

Lead-in Virological Suppression
<2 Log10 / 2-4 Log10 / ≥4 Log10 / P-value1
Patient Number / 360 / 134 / 163 / NA
Nonresponders, % / 100 / 100 / 19 / NA
Breakthrough/Relapsers, % / 0 / 0 / 81 / NA
Express, % / NA / NA / NA / NA
Age / 50.5 (7.5) / 50.8 (7.3) / 49.5 (6.4) / 0.25
Male, % / 69 / 69 / 80 / 0.03
Caucasian, % / 67 / 75 / 80 / 0.009
Body Mass Index / 30.0 (5.3) / 30.6 (6.2) / 29.2 (4.7) / 0.07
ALT/ULN / 2.21 (1.58) / 2.21 (1.72) / 2.41 (2.26) / 0.47
Log10 HCV RNA / 6.46 (0.45) / 6.34 (0.50) / 6.61 (0.49) / <0.0001
Genotype 1, % / 96 / 96 / 90 / 0.009
Ishak Inflammation / 7.5 (2.0) / 7.3 (2.1) / 7.5 (2.0) / 0.58
Ishak Fibrosis / 4.1 (1.3) / 4.2 (1.2) / 3.8 (1.2) / 0.04
Ishak Fibrosis 5-6, % / 40 / 43 / 32 / 0.12

All values represent Means (± SD) or %. NA=not applicable.

1Chi-square test or ANOVA comparing 3 groups (not trend).

Supplemental Table 3. Baseline Characteristics of Study Subjects in Figure 3 (N=328), By Virological Response

Lead-in and Randomized
Virological Suppression
<2 Log10
Any / ≥2 Log10
<2 Log10 / ≥2 Log10
≥2 Log10 / P-value1
Patient Number / 175 / 99 / 54 / NA
Nonresponders, % / 100 / 75 / 24 / NA
Breakthrough/Relapsers, % / 0 / 25 / 76 / NA
Express, % / NA / NA / NA / NA
Age / 51.2 (7.7) / 51.4 (7.3) / 49.9 (6.0) / 0.45
Male, % / 67 / 79 / 76 / 0.11
Caucasian, % / 68 / 71 / 87 / 0.02
Body Mass Index / 30.0 (5.6) / 29.7 (5.5) / 29.6 (4.6) / 0.88
ALT/ULN / 2.17 (1.43) / 2.09 (1.62) / 2.38 (2.46) / 0.59
Log10 HCV RNA / 6.49 (0.44) / 6.49 (0.52) / 6.55 (0.46) / 0.68
Genotype 1, % / 98 / 94 / 94 / 0.13
Ishak Inflammation / 7.6 (2.0) / 7.3 (2.1) / 7.7 (2.1) / 0.54
Ishak Fibrosis / 4.1 (1.2) / 3.8 (1.3) / 4.1 (1.2) / 0.35
Ishak Fibrosis 5-6, % / 39 / 31 / 44 / 0.24

All values represent Means (± SD) or %. NA=not applicable.

1Chi-square test or ANOVA comparing 3 groups (not trend).